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Abstract
We conducted a review of systematic reviews (SRs) and randomized-controlled trials (RCTs) to analyze efficacy and safety 
of cannabis-based medication in patients with mental disorders. Five data bases were systematically searched (2006—August 
2018); 4 SRs (of 11 RCTs) and 14 RCTs (1629 participants) were included. Diagnoses were: dementia, cannabis and opioid 
dependence, psychoses/schizophrenia, general social anxiety, posttraumatic stress disorder, anorexia nervosa, attention-deficit 
hyperactivity disorder, and Tourette`s disorder. Outcome variables were too heterogeneous to conduct a  meta-analysis. A 
narrative synthesis method was applied. The study quality was assessed using the risk-of-bias tool and SIGN-checklists. 
THC- and CBD-based medicines, given as adjunct to pharmaco- and psychotherapy, were associated with improvements of 
several symptoms of mental disorders, but not with remission. Side effects occurred, but severe adverse effects were men-
tioned in single cases only. In order to provide reliable treatment recommendations, more and larger RCTs with follow-up 
assessments, consistent outcome measures and active comparisons are needed.
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Introduction
Mental disorders are among the leading causes of health 
impairments [25, 77, 89, 91] involving significant changes 
in thinking, perception, emotion, behavior and relationships 
[4]. They are considered as strongly restricting conditions, 
leading to distress for both patients and their families [19]. 
The etiology of mental disorders is complex, including 
genetic, neurobiological, psychological and environmental 
factors across the lifespan [64].
Recently, the efficacy and safety of cannabis-based medi-
cines for treatment or alleviation of mental disorders has 
been tested more systematically. Cannabis is a flowering 
plant with different species producing major compounds 
such as the psychoactive component delta-9-tetrahydro-
cannabinol (THC) and cannabidiol (CBD), which have 
partially antagonistic effects [9, 52, 69]. THC can change 
mood, sensation, perception, tension, appetite, and pain; 
CBD has shown anxiolytic, antipsychotic, neuroprotective, 
anti-inflammatory and antiemetic properties [8, 34, 54, 57]. 
The medical use of herbal cannabinoids declined early in the 
twentieth century due to emerging evidence of their health 
risks and addictive potential [22]. However, growing inter-
est in the substance as medicine was renewed in the 1990s 
with the discovery of cannabinoid receptors 1 and 2 (CB1 
and CB2, respectively), endogenous ligands (endocannabi-
noids; N-arachidonoylethanolamine (anandamide/AEA) and 
2-arachidonoylglycerol (2-AG)), and enzymes as part of an 
endogenous cannabinoid system (eCB) in the brain [49, 53]. 
The eCB is regarded as a fundamental regulatory apparatus 
connected with nearly every physiological and pathological 
aspects of mammalian biology [21]. The correct interplay 
between all these endocannabinoid system elements plays 
an important role in central nervous system (CNS) develop-
ment, synaptic plasticity, motor control, memory, cognition, 
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stress, emotional responses, reward and motivated behav-
ior, appetite, pain, development and homeostasis [58, 68, 
72]. Outside the brain, the eCB system is one of the crucial 
modulators of the autonomic nervous system, the immune 
system, the endocrine network, the gastrointestinal tract, the 
reproductive system, and in microcirculation [20]. Endocan-
nabinoids are one of the most important systems controlling 
both excitatory and inhibitory neurotransmission, as well 
as neuroplasticity [72]. They serve as retrograde signaling 
messengers in GABAergic and glutamatergic synapses, as 
well as modulators of postsynaptic transmission, interacting 
with other neurotransmitters, including dopamine. Endocan-
nabinoids also participate in the modulation of the hypotha-
lamic–pituitary–adrenal (HPA) axis and regulation of stress 
[30, 75]. Preclinical and clinical data support the involve-
ment of the eCB in the etiopathogenesis of mental disor-
ders [24, 35, 44, 73]. Especially the CB1 receptor, which is 
the most abundant and widespread receptor throughout the 
mammalian brain, has become a target of interest [23, 38]. 
Reported findings from human brain studies are controver-
sial [67] since different alterations in gene and/or protein 
expression of CB1 receptors have been shown to depend on 
the technical approach used or the brain region studied [35]. 
Although the picture is complex and not fully understood, 
the neuromodulatory function of the eCB System could be 
an interesting target for pharmacotherapeutic interventions 
in mental disorders [24, 26, 50, 57, 67, 70]. The synthesis of 
cannabinoid receptor agonists and antagonists, anandamide 
uptake blockers and inhibitors of endocannabinoid anan-
damide degradation has further opened up new treatment 
strategies [26, 72].
On the other hand, cannabis is the most frequently used 
illegal substance worldwide [92] and scientific evidence 
indicates that chronic exposure to cannabinoids may increase 
mental health risks, such as impaired cognition, depression, 
anxiety, psychoses and cannabis dependence in vulnerable 
persons [27, 32, 63, 86]. On a neurophysiological basis, 
chronic use of cannabinoids can impair CB1R function; cre-
ate a loss of eCB-mediated synaptic plasticity in neural cir-
cuits, and cause addiction and negative affective states [68]. 
Based on these cannabis-related controversies, this paper is 
aimed at systematically screening the scientific literature of 
randomized-controlled trials (published between 2006 and 
2018) to assess the efficacy and safety of cannabis-based 
medicines as a treatment of mental disorders.
Methods
This systematic review followed guidance published by the 
Centre for Reviews and Dissemination and the Cochrane 
Collaboration [29]. The study protocol is registered with the 
Centre for Reviews and Dissemination at the University of 
York (UK): http://www.crd.york.ac.uk/prosp ero/Displ ayPDF 
.php?ID=CRD42 01605 3592. This work is part of a large 
cannabis expertise on potential and risks of cannabinoids 
[31] commissioned by the German Ministry of Health.
Eligibility criteria
We searched for systematic reviews (SR) and randomized-
controlled trials (RCTs) testing the efficacy and safety of 
medical cannabis (with or without additional medication 
and psychotherapy) for the treatment of mental disorders. 
Studies published in English or German language in the past 
decade were considered.
Information sources
The data bases PsycINFO, Medline, PubMed, Embase, and 
the Cochrane Library were used. Hand searches were con-
ducted, researchers in this field were contacted. Reference 
lists of included studies were screened. Search results and 
full-text articles were independently assessed by 2 review-
ers; disagreements were resolved by consensus or referral 
to a third reviewer.
Search
Based on the clinical research questions, we developed three 
detailed search strategies for identifying studies. Medical 
subject headings (“mesh-Terms”; U.S. National Library of 
Medicine 2017 https ://www.nlm.nih.gov/mesh/) were used 
to build and pilot test search strings, which were finally 
adapted to the different data bases (Table 1).
Study selection
The search process was documented in a priori defined 
research protocols. The study selection process (i.e., screen-
ing, eligibility, inclusion in review) was documented in 
PRISMA flow-charts [56] (Figs. 1, 2, 3). References are 
archived in EndNoteTM (EndNote X8, Clarivate Analytics).
Data collection process and data items
Titles and abstracts of studies retrieved using the search 
strategies were screened independently by two researchers 
to identify studies which potentially meet the inclusion 
criteria. The full text of these potentially eligible studies 
was assessed for eligibility. A standardized form was used 
to extract data from the included studies for assessment 
of study quality and evidence synthesis according to the 
PICO scheme (i.e., baseline characteristics of patients, 
interventions, comparisons and outcomes). Whereever 
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possible, the journal article was used as the primary pub-
lication because it had been peer reviewed.
Participants
Studies were included if they reported diagnostic criteria 
of mental disorders [3, 4, 93].
Interventions
Experimental condition: CB1 receptor agonists (dronabi-
nol, nabilone, nabiximols or THC), CB1 receptor antago-
nists/inverse agonists (rimonabant, drinabant), cannabi-
noid modulators (cannabidiol) or any other cannabinoid.
Control condition: placebo and/or other medication and/
or psychotherapy and/or any other intervention different 
from the experimental condition.
Outcome measures
Primary outcome was the efficacy of medical cannabinoids 
for the treatment of any mental disorder. Secondary out-
comes were tolerability and safety of medical cannabinoids.
Risk‑of‑bias assessment and level of evidence
Qualitative ratings of the selected studies were conducted by 
using standardized protocols and tools. Systematic reviews 
were assessed with the Cochrane risk-of-bias tool (http://
www.risko fbias .info/). RCTs were assessed for methodologi-
cal quality using the SIGN-checklist [76]. Data extraction 
and risk-of-bias assessment were performed independently 
by 2 reviewers; disagreements were resolved by a third 
reviewer. Each study received a level of evidence, based 
on study type and quality [65]. All documents are available 
upon request.
Fig. 1  Literature search of sys-
tematic reviews (SR) (#Search 
1) Records identified through database searching
(n = 469)
Additional records identified through 
other sources
(n = 18)
Records after duplicates removed
(n = 282)
Records screened
(n = 282)
Records excluded
(n = 249)
Full-text articles assessed 
for eligibility
(n = 33)
Full-text articles excluded, 
with reasons (n = 31)
No systematic review (1)
In other studies included (3)
Insufficient quality (1)
Not meeting criteria (26)
Studies included
(n = 2)
1 SR: Alzheimer`s disease (1 RCT)
1 SR: Schizophrenia (2 RCTs)
Social Anxiety Disorder (1 RCT), 
Tourette`s Syndrom (2 RCTs)
Sc
re
en
in
g
In
cl
ud
ed
El
ig
ib
ili
ty
Id
en
tif
ic
at
io
n
90 European Archives of Psychiatry and Clinical Neuroscience (2019) 269:87–105
1 3
Synthesis of results
This systematic review applies a qualitative data synthesis 
approach. Due to high heterogeneity of primary outcome 
measures in the identified studies, no aggregated data analy-
sis was possible. The study results were interpreted with 
respect to their sample size, level of evidence, risk of bias 
and level of heterogeneity/homogeneity.
Results
Study selection
The three searches resulted in 1031 screened records. 4 
systematic reviews (of 11 RCTs) and 14 additional RCTs 
were included (PRISMA flow-charts, Figs. 1, 2, 3). The total 
number of study participants covered in this review is 1629. 
A reference list of excluded studies is available on request.
Participants
Randomized-controlled trials assessed the following fully 
diagnosed mental disorders: Alzheimer`s disorder/demen-
tia (4 RCTs), substance use disorders [opioid dependence 
(2 RCTs); cannabis use disorder (5 RCTs)], psychoses/
schizophrenia (8 RCTs), generalized social phobia (1 RCT), 
posttraumatic stress disorder (1 RCT), anorexia nervosa (1 
RCT), Tourette`s disorder (2 RCTs), attention-deficit hyper-
activity disorder (1 RCT).
Types of interventions and comparisons
The RCTs tested CB1 receptor agonists [dronabinol (6 
RCTs), nabiximols (4 RCTs), THC (5 RCTs), nabilone (1 
RCTs), CB1 receptor antagonists/inverse agonists [rimona-
bant (2 RCTs), drinabant (1 RCTs)] or cannabinoid mod-
ulators [cannabidiol (CBD) (6 RCTs)]. In many studies 
cannabis-based medicines were given as add-on to standard 
medication and psychotherapy.
Fig. 2  Updated search of 
systematic reviews (SR) and 
randomized-controlled trials 
(RCT) (#Search 2)
Records identified through 
database searching
(n = 417)
Additional records identified through 
other sources
(n =0) 
Records after duplicates removed
(n = 260)
Records screened
(n =260)
Records excluded
(n = 249)
Full-text articles assessed 
for eligibility
(n =11)
Full-text articles excluded, 
with reasons (n = 10)
No systematic review (5)
In other studies included (2)
Insufficient quality (2)
Studies included 
(n = 1)
1 RCT: Cannabis Use Disorders
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Results of individual studies
Dementia (F0 ICD-10) 1 SR [59] of 1 RCT and 3 addi-
tional RCTs were identified [1, 82–85]. Volicer et al. [85] 
found positive effects on mean weight gain in both groups 
(dronabinol–placebo group by 3.95 kg, placebo–dronabinol 
group: by 3.13 kg) with a pronounced effect of dronabinol 
compared to placebo (p = 0.017) (Table 2). A reduction in 
Fig. 3  De novo research of 
systematic reviews (SRs) and 
randomized-controlled trials 
(RCTs)
Records identified through 
database searching
(n = 145)
Additional records identified through 
other sources
(n = 7)
Records after duplicates removed
(n = 106)
Records screened
(n =106)
Records excluded
(n = 67)
Full-text articles assessed 
for eligibility
(n = 39)
Full-text articles excluded, 
with reasons
(n = 24)
No SR or RCT (13)
Newer version included (3)
In other studies included (3)
In global search included (2)
Insufficient quality (3)
Studies included 
(n = 15)
1 SR: Schizophrenia (4 RCTs)
1 SR: Anorexia Nervosa (1 RCT)
3 RCTs: Alzheimer`s Disease 
4 RCTs: Cannabis Use Disorder
2 RCTs: Opioid Dependence
2 RCTs: Schizophrenia
1 RCT: Posttraumatic Stress Disorder
1 RCT: Attention-Deficit Hyperactivity 
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Table 1  Search process, medical subject headings (MeSH)
Search process MeSH-terms and search setting
Search 1 (2006–2016) Cannabis OR cannabinoid* OR hemp OR hanf (ti, ab) OR 2) Mariuana OR Marihuana OR Marijuana (ti, ab)
Search 2 (2014–2016) Medical marihuana OR medical marijuana OR medical mariuana OR medical cannabis OR pharmaceutical 
marihuana OR pharmaceutical marijuana OR pharmaceutical mariuana OR pharmaceutical cannabis (ti, 
ab)
Search 3 (–2018) Medical Marijuana OR Cannabinoids OR Cannabinol OR Cannabidiol OR Dronabinol (all fields), (2) 
Mental Disorders OR Psychotic Disorders OR Schizophrenia OR Depression OR Depressive Disorder OR 
Dysthymic Disorder OR Bipolar Disorder OR Anxiety Disorders OR Stress Disorders OR Post-Traumatic 
OR Obsessive–Compulsive Disorder OR Tourette Syndrome OR Sleep Wake Disorders OR Alzheimer 
Disease OR Anorexia Nervosa OR Substance-Related Disorders (all fields) (3) 1 AND 2 (4) Limit 3 to 
((human AND (meta-analysis or “systematic review”)) OR (human and randomized controlled trial)) AND 
(English or German)
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negative affect (anger, anxiety and sadness) was detected 
during the treatment with dronabinol, which persisted dur-
ing the episode following the treatment with dronabinol 
(ANOVA:  F(order × treatment) = 2.78, df = 1, 143, p = 0,12). No 
effects were found for caloric intake. Three patients dropped 
out of the study [adverse effects (n = 1), severe infections 
(n = 2), myocardial infarction during the placebo phase 
(n = 1)]. In a multi-centered RCT (Table 3) van den Elsen 
et al. [82] reported that THC did not reduce neuropsychiatric 
symptoms compared to placebo (block 1–3: 1.8, 97.5% CI 
− 2.1 to 5.8; block 4–6: − 2.8, 97.5%CI − 7.4 to 1.8). Psy-
chiatric symptoms, agitated behavior and caregiver burden 
increased in both study arms during the 12 weeks trial. THC 
was well tolerated, as assessed by adverse event monitoring, 
vital signs and mobility. The incidence of adverse events was 
similar between treatment groups. Four non-related serious 
adverse events occurred. In a sample of ten patients, Ahmed 
et al. [1] reported that THC was rapidly absorbed and had 
dose-linear pharmacokinetics with considerable variation. 
Pharmacodynamic effects, including adverse events, were 
minor. Another RCT with cross-over design [84] tested the 
efficacy and safety of low-dose oral THC (3 × 1–5 mg/day, 
3 weeks.) or placebo. Neuropsychiatric symptoms were 
reduced during both treatment conditions, with no differ-
ence between THC and placebo (mean difference  NPItotal: 
3.2, 95% CI 23.6–10.0). No changes in scores for agitation, 
quality of life, or activities of daily living were found. The 
number of patients experiencing mild or moderate adverse 
events was similar (THC: n = 16, placebo: n = 14; p = 0.36). 
No effects on vital signs, weight, or episodic memory were 
observed. In all trials, patients could continue their standard 
medication. In summary, the studies provide a heterogene-
ous picture: superior effects (weight gain and reduction in 
negative affect) of THC (given in addition to standard treat-
ment and compared to placebo) were only found in one out 
of three trials. Adverse effects occurred in all conditions.
Opioid dependence (F11.20 ICD-10) Severity of with-
drawal, retention in treatment or safety were assessed in 2 
RCTs (3 reports, 70 patients) [12, 37, 48] (Table 3). The 
first intervention [12] was dronabinol (titrated to 30 mg/day, 
3 weeks) (n = 40) compared to placebo (n = 20). Patients 
were stabilized with buprenorphine (2 × 4 mg/day) (day 
2) and received naltrexone from day 5 onwards. The study 
revealed a significant initial reduction in the severity of 
the opioid withdrawal during the initial 8-day detoxifica-
tion phase for dronabinol (up to 30 mg/day) compared to 
placebo (p = 0.006). No significant difference was found in 
retention between the groups (35% retained in either group). 
The rate of successful induction onto XR-naltrexone did not 
differ between dronabinol (66%) and placebo (55%) groups 
(χ2 = 1.46, p = 0.23). A high number of AEs (96% vs. 91%) 
was reported. They were considered to be consistent with 
symptoms of naltrexone-related protracted withdrawal. Jicha 
et al. [37] and Lofwall et al. [48] tested the safety of dronabi-
nol with n = 12 adults physically dependent on short-acting 
opioids. Participants were maintained on oral 30 mg oxyco-
done. The study showed that a higher dosage of dronabinol 
(40 mg/day) produced sustained sinus tachycardia accom-
panied by anxiety and panic necessitating dose reduction 
to 30 mg. Compared to placebo, 20 and 30 mg dronabinol 
produced significant increases in heart rate beginning 1 h 
after drug administration which lasted approximately 2 h 
(p < 0.05). Dronabinol 5 and 10 mg produced placebo-like 
effects. Altogether, the evidence for the usefulness of dron-
abinol as adjunct medication in the detoxification of opioid-
dependent patients is still very small. Only one study shows 
a reduction in the severity of the opioid withdrawal in the 
initial detoxification phase. The number of reported adverse 
events was high in one study (naltrexone-related protracted 
withdrawal) while safety concerns were given in the second 
study for dronabinol at 20 mg and higher given in combina-
tion with oral oxycodone.
Cannabis dependence (F12.2 ICD-10) Craving, with-
drawal and abstinence from cannabis were assessed in 5 
RCTs (319 participants) in patients with cannabis depend-
ence [2, 42, 43, 79, 80]. Trigo et al. [80] (Table 3) added 
nabiximols or placebo to a manualized motivational 
enhancement therapy and cognitive behavioral therapy. 
Rates of adverse events did not differ between treatment 
arms (F1,39= 0.205, ns). There was no significant change 
in abstinence rates at trial end. Cannabis use decreased in 
either group, without significant differences between treat-
ment conditions (p = 0.179). Nabiximols reduced canna-
bis craving, but no significant differences between groups 
were observed on withdrawal scores. No serious adverse 
events were reported. In a previous multi-centered RCT 
with cross-over design, Trigo et al. [79] tested the effects 
of nabiximols on both craving and withdrawal symptoms 
among n = 9/16 non-treatment seeking cannabis-dependent 
adults. High fixed doses of nabiximols were well tolerated 
and, compared to placebo, significantly reduced symptoms 
of cannabis withdrawal during abstinence, but not craving. 
Self-titrated doses were lower and showed limited efficacy 
compared to high fixed doses. Participants reported a sig-
nificantly lower “high” following nabiximols or placebo as 
compared to treatment as usual conditions. Nausea, diar-
rhea and sleep disorders were reported, but no serious AEs. 
Levin et  al. [43] assessed abstinence (= 21 consecutive 
days), withdrawal, craving, and adverse events. The inter-
vention was dronabinol (self-titrated up to 3 × 20 mg/day), 
lofexidine (self-titrated up to 3 × 0.6 mg/day) or placebo. In 
both conditions, patients received cannabis-specific manual-
ized behavioral therapy. The trial found no treatment effect 
in achieving abstinence. Drop-out rates were high (48% vs. 
42%). More AEs were found in the dronabinol group (e.g., 
dry mouth, intoxication, and hypotension), serious AEs (2 
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cases) were reported in the placebo lead-out phase. In a pre-
vious double-blind RCT, Levin et al. [42] tested dronabinol 
(2 × 20 mg/day) or placebo in addition to weekly motiva-
tional enhancement and relapse prevention therapy. There 
was no significant difference between treatment groups in 
the proportion of participants who achieved 2 weeks of 
abstinence at the end of the maintenance phase (dronabi-
nol: 17.7%; placebo: 15.6%). Both groups reduced cannabis 
use over time (no differences between groups). Treatment 
retention was significantly higher at the end of the main-
tenance phase on dronabinol (77%), compared to placebo 
(61%) (p = 0.02). Withdrawal symptoms were significantly 
lower on dronabinol than placebo (p = 0.02). Dronabinol 
was well-tolerated. Allsop et al. [2] assessed the effects of 
nabiximols or placebo combined with standardized psycho-
social interventions. Nabiximols significantly reduced the 
overall severity of cannabis withdrawal relative to placebo 
(p = 0.01), including effects on withdrawal-related irritabil-
ity, depression, and cannabis cravings. Nabiximols patients 
remained longer in treatment during medication use (unad-
justed hazard ratio, 3.66 [95% CI, 1.18–11.37]; p = 0.02), 
with a number needed to treat of 2.84 to achieve successful 
retention in treatment. The frequency (p = 0.59) and sever-
ity (p = 0.10) of adverse events did not differ significantly 
between groups. Both groups showed reduced cannabis use 
at follow-up, with no advantage of nabiximols over placebo 
for self-reported cannabis use (p = 0.75), cannabis-related 
problems (p = 0.14), or cannabis dependence (p = 0.89). In 
sum, existing trials provide a heterogeneous picture of the 
effectiveness of dronabinol and nabiximols in the treatment 
of cannabis use disorders. Four studies did not find posi-
tive effects regarding abstinence or reduction in cannabis 
use. Three out of five RCTs showed a significant reduction 
of withdrawal symptoms. Two out of three trials indicate 
improved craving and one study indicates improved retention 
in treatment. Adverse effects were more frequently reported 
in the intervention group in two of three studies. Future stud-
ies should use consistent outcome variables (e.g., assessment 
of abstinence) and treatments (manualized CBT/relapse pre-
vention) in order to provide comparable findings.
Psychoses/Schizophrenia (F20 ICD-10) Two system-
atic reviews [45, 90] of 6 RCTs [13, 15, 46, 55, 74, 81] 
and two new RCTs [16, 51] were found (n = 887 partici-
pants). In the studies of Leweke and colleagues individuals 
with psychosis received CBD (800 mg/day, 4 weeks) [46] 
or CBD (600 mg/day, 2 weeks) [81]. The comparisons 
were amisulpride (max 800 mg/day) and placebo, respec-
tively. Primary outcomes were psychiatric symptoms [66] 
and positive and negative symptoms [39]. Both studies 
found significant improvements vs. baseline on days 14 
and 28 for CBD and amisulpride; no difference was found 
between groups. The authors reported side effects for all 
medications, but the side-effect profile (extrapyramidal 
symptoms, weight gain, prolactin values) was consid-
ered superior for CBD vs. amisulpride [46]. McGuire 
et al. [51] conducted a double-blind parallel-group trial 
where patients with chronic schizophrenia received CBD 
(1000 mg/day; n = 43) or placebo (n = 45) add-on to the 
existing antipsychotic medication. Participants were 
assessed before and after treatment using the Positive 
and Negative Syndrome Scale [39], the Global Assess-
ment of Functioning scale (GAF) [40], Brief Assess-
ment of Cognition in Schizophrenia (BACS) [41] and the 
improvement and severity scales of the clinical global 
impression scale [17] (CGI-I and CGI-S). After 6 weeks 
of treatment, compared to the placebo group, the CBD 
group had lower levels of positive symptoms (PANSS: 
treatment difference = − 1.4, 95% CI = − 2.5, − 0.2) and 
were more likely to have been rated as improved (CGI-I: 
treatment difference = − 0.5, 95% CI = − 0.8, − 0.1) and as 
not severely unwell (CGI-S: treatment difference = − 0.3, 
95% CI = − 0.5, 0.0) by the treating clinician. Patients 
who received CBD also showed greater improvements 
which fell short of statistical significance in cognitive 
performance (BACS: treatment difference = 1.31, 95% 
CI = − 0.10, 2.72) and in overall functioning (GAF: treat-
ment difference = 3.0, 95% CI = − 0.4, 6.4). CBD was 
well tolerated, while rates of adverse events were similar 
between the CBD and placebo groups. Boggs et al. [16] 
conducted a 6-week parallel-group RCT. The intervention 
was a fixed-dose study of oral CBD (600 mg/day) or pla-
cebo augmentation in n = 36 stable antipsychotic-treated 
patients diagnosed with chronic schizophrenia. This study 
compared the cognitive, symptomatic, and side effects 
of CBD vs. placebo in a clinical trial. No main effect of 
time or drug on MATRICS Consensus Cognitive Battery 
[10], but a significant drug × time effect was observed 
(p = 0.02). Post hoc analyses revealed that only placebo-
treated subjects improved over time (p = 0.03). There was 
a significant decrease in PANSS total scores over time 
(p < 0.0001), but there was no significant drug × time 
interaction (p = 0.18). Side effects were similar between 
CBD and placebo, with exception being sedation, which 
was more prevalent in the CBD group. Overall, CBD was 
well tolerated with no worsening of mood, suicidality or 
movement side effects. Leweke et al. [45] (LoE: 2; ROBIS: 
high) included 3 further published double-blind RCTs (of 
unclear risk of bias). The interventions were Rimonabant 
[15, 55] and drinabant (AVE1625) [74] compared to pla-
cebo (n = 3). The two CB1R antagonists/inverse agonists 
tested in schizophrenia had no significant effects on psy-
chopathology and cognition. Rimonabant and drinabant 
(AVE1625) were withdrawn from worldwide marketing 
due to psychiatric side effects [45]. Altogether, cannabid-
iol plus existing antipsychotic medication showed ben-
eficial effects. Improvements in psychotic symptoms and 
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cognition were not superior to antipsychotic medication 
or placebo in 3 studies. More studies with larger sample 
sizes are needed to systematically investigate these effects.
Generalized social phobia (ICD 10 F40.11) One system-
atic review [90] including 1 RCT [11]. This RCT tested the 
effects of one experimental session of a simulated public 
speaking test on treatment-naive individuals with general-
ized social anxiety disorder (n = 36). Participants received 
either a single dose of CBD (600 mg; n = 12) or placebo 
(n = 12). Both groups were compared to healthy controls 
(n = 12). Subjective ratings on the Visual Analogue Mood 
Scale (VAM) [33, 88] and physiological measures (blood 
pressure, heart rate, skin conductance) were measured at 
six different time points during the tests. Medication with 
CBD significantly reduced anxiety, cognitive impairment 
and discomfort in their speech performance, and signifi-
cantly decreased alert in their anticipatory speech. The pla-
cebo group presented higher anxiety, cognitive impairment, 
discomfort and alert levels when compared with the control 
group. No significant differences were observed between 
the CBD group and healthy controls in the negative self-
statement scores, cognitive impairment, discomfort, and 
alert factors. The increase in anxiety induced by the public 
speaking tests on subjects with generalized social anxiety 
disorders was reduced with the use of CBD, resulting in a 
similar response as the healthy controls. No adverse effects 
were found for CBD. More studies with larger sample sizes 
are needed to replicate the results of this study.
Posttraumatic stress disorder (ICD 10 F43.12) One RCT 
(n = 10 participants) [36] assessed recurrent distressing 
nightmares in a sample of Canadian male military person-
nel with PTSD (DSM-IV). The intervention was nabilone 
(0.5 mg, titrated to the effective dose (nightmare suppres-
sion) or reaching a maximum of 3.0 mg/7 weeks). Subjects 
were allowed to continue psychotherapy and any other 
medication. The mean reduction in nightmares as meas-
ured by the CAPS Recurring and Distressing Dream scores 
[14] were − 3.6 ± 2.4 and − 1.0 ± 2.1 in the intervention 
and control group (p = 0.03). Mean global improvement 
as measured by the Clinical Global Impression of Change 
(CGI-C) [17] was 1.9 ± 1.1 (i.e., much improved) and 
3.2 ± 1.2 (i.e., minimally improved) in the intervention and 
control group (p = 0.05). Five out of 10 (50%) were much 
improved on nabilone vs. 1 out of 9 (11%) on placebo. For 
the General Well-Being Questionnaire [71] improvements 
were 20.8 ± 22 and − 0.4 ± 20.6 in the nabilone and placebo 
groups, respectively (p = 0.04). No improvement of sleep 
intensity and quality was reported. Every second partici-
pant reported adverse events (nabilone group: 50%; control 
group: 60%). No event was severe nor resulted in a drop-out. 
More studies with larger sample sizes are needed to replicate 
these study results.
Anorexia nervosa (ICD 10 F50.0) One systematic 
review [28] of 1 RCT [5–7] was found. This study tested 
the effects of dronabinol (2 × 2.5 mg/day; 4 weeks) as 
add-on to standard psychotherapy and eating management 
in a sample of women with severe (> 5 years) anorexia 
nervosa (DSM-IV-TR) (n = 25). Primary outcomes were 
weight, behaviors and beliefs (Eating-Disorder Inventory 
II) [78] as well as physical activity. The trial found weight 
gain in both groups, with larger effects in the active treat-
ment group (1 kg) vs placebo (0.34 kg). No changes were 
found in the Eating-Disorder Inventory and in the dura-
tion of physical activity. Adverse effects were reported 
in both groups (no serious adverse effects). More stud-
ies with larger sample sizes are needed to replicate these 
results.
Attention-deficit hyperactivity disorder (ADHD) (ICD 
10 F90) The effects of Nabiximols compared to placebo 
were tested in one RCT (n = 30 adults) [18]. Patients cur-
rently treated with stimulants were asked to stop their 
medication for 1 week before their baseline assessments 
and for the duration of the study. Patients on long-acting 
medications, such as atomoxetine, were excluded from the 
study. The primary outcome was cognitive performance 
and activity level; secondary outcomes included ADHD 
and emotional lability symptoms. For the primary out-
come, no significant difference was found (ITT-analysis) 
(Est = − 0.17, 95% CI − 0.40 to 0.07, p = 0.16). For sec-
ondary outcomes, improvements in hyperactivity/impul-
sivity (p = 0.03) and a cognitive measure of inhibition 
(p = 0.05) were found, but not in inattention (p = 0.10) 
or emotional lability (p = 0.11). Results did not meet 
significance following adjustment for multiple testing. 
One serious (muscular seizures/spasms) and three mild 
adverse events occurred in the active group and one seri-
ous adverse event (cardiovascular problems) in the pla-
cebo group. More studies with larger sample sizes are 
needed to replicate the results of this study.
Tourette’s disorder (ICD 10 F95) One systematic 
review [90] identified 2 RCTs (3 reports, n = 36 Patients) 
[60–62] in which therapy-resistant Tourette`s disorder 
(n = 12/n = 24) were assessed. The interventions were 
THC (1 × max. 10 mg) and THC (titrated to 10.0 mg/
day, 6 weeks), respectively. Comparisons were placebos 
(identical in taste and appearance). Multiple outcome var-
iables were assessed (e.g., Tourette`s Syndrome Clinical 
Global Impressions Scale), Shapiro Tourette-Syndrome 
Severity Scale, Yale Global Tic Severity Scale (YGTSS) 
[87]. Both studies found improvement in various Tou-
rette-related outcomes, of which not all reached statisti-
cal significance. Adverse effects were reported in both 
groups (no serious adverse effects). More studies with 
larger sample sizes are needed to replicate the results of 
these two studies.
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Synthesis of results
Due to a large heterogeneity of patient groups, interventions, 
comparisons and outcome criteria, data were not sufficient 
to calculate effect sizes and odds ratios.
Discussion
Only recently, cannabis-based medicine was tested more sys-
tematically for the treatment of mental disorders. The aim of 
this systematic review was to analyze its efficacy, tolerabil-
ity and safety in patients with a diagnosed mental disorder. 
The literature research identified 4 SRs (of 11 RCTs) and 
14 additional RCTs. A total of 1629 patients was examined, 
meeting criteria of 9 classified diagnoses of mental disorders 
(DSM-III-R, DSM-IV, DSM-5). Across studies, methodo-
logical limitations reduced the confidence in the evidence 
for several reasons: (1) for most indications, only single 
RCTs with small sample sizes (e.g., general social anxiety 
disorder, attention-deficit hyperactivity disorder) have been 
published. (2) In cases where more studies are available, 
results were mixed (e.g., dementia, cannabis use disorders) 
or did not consistently reach statistical significance (e.g., 
schizophrenia). A large variety of outcome variables were 
used and they were not comparable across studies.
The scientific literature shows, that among all cannabis-
based medicines, THC-based preparations have been tested 
most frequently as treatment for mental disorders: Nabixi-
mols (4 RCTs) [2, 18, 79, 80], dronabinol (6 RCTs) [5–7, 
12, 42, 43, 48, 85], THC (5 RCTs) [1, 60–62, 82, 83], and 
nabilone [36]. All trials were placebo-controlled; other 
medication (e.g., benzodiazepines) and psychotherapy were 
available in most studies.
The largest number of controlled studies (7 RCTs) and 
thus best evidence available, is for THC-based medicine 
(nabiximols, dronabinol) as an adjunct to other interven-
tions in the treatment of substance use disorders (canna-
bis dependence, opioid dependence). In cannabis depend-
ent patients, a reduction of cannabis withdrawal symptoms 
was found in 3 RCTs [2, 42, 79], but not found in 2 studies 
[43, 80]. Two out of three trials reported improved craving 
and one study indicates improved retention in treatment. 
Significant effects on abstinence or a reduction in substance 
use were not found between intervention and comparison 
groups. Adverse effects were more frequently reported in 
the intervention group in two of three studies. Future studies 
should use consistent outcome variables (e.g., assessment of 
abstinence) and treatments (manualized CBT/relapse preven-
tion) to provide comparable findings. Among opioid depend-
ent patients, a reduction in the severity of opioid withdrawal 
was reported in one study [12]. The evidence of THC-based 
preparations in the treatment of further mental disorders is 
also small, the effects are mixed. In Alzheimer`s disease 
results are inconsistent for the improvement of neuropsy-
chiatric symptoms, mood and agitation in patients (3 RCTs) 
[82, 83, 85]. A consistent improvement of tics and behavio-
ral problems was found in 2 studies including patients with 
therapy-resistant Tourette`s disorder. Not all results reached 
statistical significance [60–62]. For all other mental disor-
ders, only single studies are available regarding the efficacy 
of THC-based medicine in these conditions. The reported 
therapeutic benefits in primary outcomes are: weight gain 
in patients with therapy-resistant anorexia nervosa (1 RCT) 
[5–7], improvement of nightmares and well-being in patients 
with posttraumatic stress disorder (1 RCT) [36]. In patients 
with attention-deficit hyperactivity disorder improvement in 
cognition and activity level did not reach statistical signifi-
cance (1 RCT) [18]. Adverse events occurred in all studies, 
with no difference between groups. However, safety con-
cerns appeared during opioid withdrawal for dronabinol at 
20 mg and higher [12].
Cannabidiol as a treatment of mental disorders was tested 
in 6 RCTs. Most data is available for patients with psycho-
ses and schizophrenia. Cannabidiol (CBD) plus existing 
antipsychotic medication was associated with significantly 
lower levels of positive symptoms compared with the pla-
cebo group in 1 RCT [51]. Three further RCTs also found 
improvements in both psychotic symptoms and cognition, 
which fell short of statistical significance if compared to 
antipsychotic medication [46] or placebo [16, 81]. Positive 
anxiolytic effects of CBD were shown in patients with gen-
eralized social anxiety compared to a placebo group and 
healthy controls (1 RCT) [11]. No adverse effects have been 
reported for cannabidiol as treatment for mental disorders.
Other cannabis-based medicines were rimonabant and 
drinabant, which have been tested in 3 RCTs for the treat-
ment of schizophrenia [15, 55, 74]. These studies found no 
benefits on cognition and psychiatric symptoms. Due to seri-
ous adverse effects, rimonabant and drinabant were with-
drawn from the market.
In summary, the evidence for efficacy and safety of can-
nabis-based medicines as a treatment for mental disorders 
is still small. Reported improvements were mostly assessed 
in single RCTs with small sample sizes. In order to get a 
clearer picture of potential therapeutic effects, to reveal dif-
ferential indications (which group of patients is most likely 
to benefit from cannabis preparations) and to allow a gener-
alization towards naturalistic samples of patients, more clini-
cal research of high methodological quality is needed. The 
required studies should be multi-centered, randomized and 
controlled, including large samples sizes. The currently 
existing trials generally tested cannabis-based medication for 
a few days up to several weeks. No follow-up assessments 
were conducted. Long-term data, however, are essential to 
get information on optimal treatment duration, sustained 
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cannabinoid effects (e.g., tolerance, symptoms of with-
drawal, cognition, quality of life, level of functioning) and 
safety. Consistent outcome measures (e.g., disorder remis-
sion, change in symptom severity, hospitalization, patient 
or care person’s perception of improvement) should be used 
to assess the efficacy of cannabis medicine. Furthermore, 
to assess the potential of cannabis-based medicine in com-
parison to existing treatment options, future studies should 
have active control groups such as first-line pharmacological 
treatments (e.g., antidepressants, antipsychotic medication) 
and psychosocial treatments (e.g., manualized cognitive 
behavioral therapy) as comparisons.
Conclusion
THC- and CBD-based medicines were associated with 
improvements of several symptoms of mental disorders, but 
not with remission. Side effects can occur, but severe AEs 
were mentioned in single cases only. The overall confidence 
in the evidence is low. To provide reliable treatment rec-
ommendations, more high-quality RCTs with larger sample 
sizes are requested.
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